538 related articles for article (PubMed ID: 16046462)
21. In vitro susceptibility of yeasts isolated from patients in intensive care units to fluconazole and amphotericin B during a 3-year period.
Kucukates E; Erturan Z; Susever S; Yegenoglu Y
APMIS; 2005 Apr; 113(4):278-83. PubMed ID: 15865609
[TBL] [Abstract][Full Text] [Related]
22. Emergence of non-albicans Candida species and antifungal resistance in a tertiary care hospital.
Capoor MR; Nair D; Deb M; Verma PK; Srivastava L; Aggarwal P
Jpn J Infect Dis; 2005 Dec; 58(6):344-8. PubMed ID: 16377864
[TBL] [Abstract][Full Text] [Related]
23. Susceptibilities to amphotericin B and fluconazole of Candida species in Taiwan Surveillance of Antimicrobial Resistance of Yeasts 2006.
Yang YL; Wang AH; Wang CW; Cheng WT; Li SY; Lo HJ;
Diagn Microbiol Infect Dis; 2008 Jun; 61(2):175-80. PubMed ID: 18304773
[TBL] [Abstract][Full Text] [Related]
24. Fungaemia caused by Candida glabrata with reduced susceptibility to fluconazole due to altered gene expression: risk factors, antifungal treatment and outcome.
Tumbarello M; Sanguinetti M; Trecarichi EM; La Sorda M; Rossi M; de Carolis E; de Gaetano Donati K; Fadda G; Cauda R; Posteraro B
J Antimicrob Chemother; 2008 Dec; 62(6):1379-85. PubMed ID: 18782778
[TBL] [Abstract][Full Text] [Related]
25. Therapies against murine Candida guilliermondii infection, relationship between in vitro antifungal pharmacodynamics and outcome.
Paredes K; Pastor FJ; Capilla J; Sutton DA; Mayayo E; Fothergill AW; Guarro J
Rev Iberoam Micol; 2015; 32(1):34-9. PubMed ID: 24594291
[TBL] [Abstract][Full Text] [Related]
26. Alternative dosing regimens of liposomal amphotericin B (AmBisome) effective in treating murine systemic candidiasis.
Adler-Moore JP; Olson JA; Proffitt RT
J Antimicrob Chemother; 2004 Dec; 54(6):1096-102. PubMed ID: 15509617
[TBL] [Abstract][Full Text] [Related]
27. Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis.
Gumbo T; Drusano GL; Liu W; Ma L; Deziel MR; Drusano MF; Louie A
Antimicrob Agents Chemother; 2006 Nov; 50(11):3695-700. PubMed ID: 16954319
[TBL] [Abstract][Full Text] [Related]
28. Management of mycoses in surgical patients -- review of the literature.
Holzheimer RG; Dralle H
Eur J Med Res; 2002 May; 7(5):200-26. PubMed ID: 12069912
[TBL] [Abstract][Full Text] [Related]
29. Effect of antifungal treatment in a murine model of blastoschizomycosis.
Serena C; Mariné M; Marimon R; Pastor FJ; Guarro J
Int J Antimicrob Agents; 2007 Jan; 29(1):79-83. PubMed ID: 17134881
[TBL] [Abstract][Full Text] [Related]
30. [In vitro activity of amphotericin B, fluconazole and itraconazole against Candida glabrata strains isolated from clinical samples].
Hüseyin A; Sancak B; Arikan S
Mikrobiyol Bul; 2007 Apr; 41(2):235-44. PubMed ID: 17682710
[TBL] [Abstract][Full Text] [Related]
31. Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp.
Messer SA; Diekema DJ; Boyken L; Tendolkar S; Hollis RJ; Pfaller MA
J Clin Microbiol; 2006 Feb; 44(2):324-6. PubMed ID: 16455878
[TBL] [Abstract][Full Text] [Related]
32. Candida tropicalis in human disease.
Chai LY; Denning DW; Warn P
Crit Rev Microbiol; 2010 Nov; 36(4):282-98. PubMed ID: 20883082
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis.
Schwarz P; Dromer F; Lortholary O; Dannaoui E
Antimicrob Agents Chemother; 2006 Jan; 50(1):113-20. PubMed ID: 16377675
[TBL] [Abstract][Full Text] [Related]
34. The effect of aminocandin (HMR 3270) on the in-vitro adherence of Candida albicans to polystyrene surfaces coated with extracellular matrix proteins or fibronectin.
Cateau E; Levasseur P; Borgonovi M; Imbert C
Clin Microbiol Infect; 2007 Mar; 13(3):311-5. PubMed ID: 17391387
[TBL] [Abstract][Full Text] [Related]
35. Combined therapy in treatment of murine infection by Fusarium solani.
Ruíz-Cendoya M; Mariné M; Guarro J
J Antimicrob Chemother; 2008 Sep; 62(3):543-6. PubMed ID: 18495651
[TBL] [Abstract][Full Text] [Related]
36. Comparison of the kidney fungal burden in experimental disseminated candidiasis by species of the Candida parapsilosis complex treated with fluconazole, amphotericin B and caspofungin in a temporarily neutropenic murine model.
Szilágyi J; Földi R; Gesztelyi R; Bayegan S; Kardos G; Juhász B; Majoros L
Chemotherapy; 2012; 58(2):159-64. PubMed ID: 22626860
[TBL] [Abstract][Full Text] [Related]
37. In vitro susceptibility of oral Candida to seven antifungal agents.
Kuriyama T; Williams DW; Bagg J; Coulter WA; Ready D; Lewis MA
Oral Microbiol Immunol; 2005 Dec; 20(6):349-53. PubMed ID: 16238594
[TBL] [Abstract][Full Text] [Related]
38. Combination therapy with amphotericin B and fluconazole against invasive candidiasis in neutropenic-mouse and infective-endocarditis rabbit models.
Sanati H; Ramos CF; Bayer AS; Ghannoum MA
Antimicrob Agents Chemother; 1997 Jun; 41(6):1345-8. PubMed ID: 9174196
[TBL] [Abstract][Full Text] [Related]
39. Pradimicin therapy of disseminated Candida tropicalis infection in the mouse.
Restrepo MI; Najvar LK; Fothergill AW; Graybill JR
Med Mycol; 1998 Jun; 36(3):181-4. PubMed ID: 9776832
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic efficacy of voriconazole against a fluconazole-resistant Candida albicans isolate in a vaginal model.
González GM; Portillo OJ; Uscanga GI; Andrade SE; Robledo M; Rodríguez C; Elizondo M
J Antimicrob Chemother; 2009 Sep; 64(3):571-3. PubMed ID: 19570754
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
